Targeting oral cancer with MicroRNA-based therapeutics: The role of tumor-suppressor miRNAs and exosome delivery.
Janivarad T., Kumbar VM., Marakatti R., Kotabagi S., Kambi M., Lolsure K.
Narrative Review, published in Arch Oral Biol (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Arch Oral Biol (2026)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41814117
- DOI
- 10.1016/j.archoralbio.2026.106562
Abstract (original English)
Objective To evaluate the potential of tumor-suppressor microRNAs delivered via exosomes, especially those from human dental pulp stem cells, as a targeted therapy for oral cancer and to examine recent strategies that improve their delivery and clinical application. Although extensive preclinical evidence supports the anticancer functions of TS-miRNAs, the robustness and reproducibility of their effects vary substantially across experimental models. Exosome-based delivery has emerged as a biologically attractive strategy to improve miRNA stability, targeting specificity, and therapeutic efficacy. Design This review examines preclinical and translational studies on the delivery of tumor-suppressor microRNAs using exosomes, focusing on human dental pulp stem cell derived exosomes and recent strategies that enhance their targeting and therapeutic effectiveness. Relevant studies were identified through PubMed, Scopus, Web of Science, and Google Scholar. Results Studies show that using exosomes to deliver tumor-suppressor microRNAs can make them more stable, help them enter cells more efficiently, and reach tumors more effectively. Among multiple clinically relevant sources, including bone marrow and adipose-derived mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and tumor-derived vesicles, human dental pulp stem cell (hDPSC)-derived exosomes represent a promi
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.